June 2009 when AZAs were identified in US seafood for the first time resulting in human intoxications and further expanding their global distribution. Efforts are now underway in several laboratories to better define the effects and mechanism(s) of action for the AZAs. Our investigations have employed Jurkat T lymphocyte cells as an in vitro model to characterize the toxicological effects of AZA1, AZA2, and AZA3. Cytotoxicity experiments employing a metabolically-based dye (i.e., MTS) indicated that AZA1, AZA2, and AZA3 each elicited a lethal response that was both concentration-and time-dependent, with EC 50 values in the sub-to low nanomolar range. Based on EC 50 comparisons, the order of potency was as follows: AZA2 > AZA3 > AZA1, with toxic equivalence factors (TEFs) relative to AZA1 of 8.3-fold and 4.5-fold greater for AZA2 and AZA3, respectively. Image analysis of exposed cells using Nomarski differential interference contrast (DIC) imaging and fluorescent imaging of cellular actin indicated that the morphological effects of AZA1 on this cell type are unique relative to the effects of AZA2 and AZA3. Collectively, our data support the growing body of evidence suggesting that natural analogs of AZA are highly potent and that they may have multiple molecular targets. Toxicology   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 5 KEYWORDS: azaspiracid (AZA), cytotoxicity, potency, structure-activity relationship, T lymphocytes, toxic equivalence factor (TEF) Toxicology   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Morocco (4), Chile (5), and Canada (M. Quilliam, pers. comm). AZAs were also recently detected in marine sponges (6). Human symptoms following intoxication include nausea, vomiting, and stomach cramps (7), but thus far no deaths have been attributed to AZAs.
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The AZA group now includes more than 20 analogs that are produced either by phytoplankton, through biotransformation in shellfish, or as by-products formed during processing and storage of toxin-containing tissues (7-9). Although there is geographical variation, plankton samples are dominated by AZA1 and AZA2 (Figure 1) , with the former often constituting over 80% of the toxin profile (1, 10) . The recent isolation and culturing of A. spinosum has further confirmed these findings (1, 11) , but interestingly, other non-toxigenic Azadinium species have now been described (12). Naturally contaminated shellfish often remain above the European regulatory action level for many months following exposure to AZAs (13, 14) . Toxin binding proteins may be responsible, in part, for this slow rate of depuration in certain shellfish (15, 16).
Studies in mice exposed orally to AZA1 revealed severe gastrointestinal tract deterioration, adverse histopathologies of the liver, spleen, and thymus, as well as a small incidence of tumor formation (17, 18). The minimal lethal doses for AZA1 are ca. 500 µg/kg (oral) (19) and ca. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 respectively, of AZA3. Although these experimental data are extremely valuable, their clear interpretation has been hindered due to the use of material of unknown purity. Nonetheless, this information has provided the guidance needed to propose toxic equivalence factors (TEFs) (1.0, 1.8, and 1.4 for AZA1, AZA2, and AZA3; respectively) that are used for determining the total AZA equivalent concentrations in European shellfish (23). The EU regulatory limit is 0.16 µg/g "total" AZAs in shellfish as detected by LC-MS/MS. Only AZA1-3 are currently regulated.
Multiple studies have demonstrated the in vitro cytotoxic potential of AZA1 wherein every cell type tested to date appears to be susceptible (see Twiner et al. (7) for a review). AZAs are very potent cytotoxic compounds (6, 24, 25) , induce irreversible cytoskeletal rearrangements in mammalian cells (24, 26, 27) , stimulate secondary messenger molecules (28, 29) , deplete cellular ATP (30) , inhibit neuronal ion flux and bioelectrical activity (31, 32) , induce cell volume reductions followed by c-Jun N-terminal kinase (JNK) activation (33, 34) , inhibit membrane protein endocytosis (35) , and up-regulate low density lipoprotein receptor as well as stimulating cholesterol biosynthesis (36) . AZA1 has also been shown to be a potent teratogen in developing fish embryos (37) . In many cases the toxin concentrations necessary to observe these various effects are in the low nanomolar range (7, 31, 34, 35) , but for some endpoints they approach or exceed micromolar concentrations (31, 38) . Despite the efforts of many investigators, the mechanism(s) of action of AZAs has not yet been determined.
The possible involvement of an apoptotic pathway in AZA1 cytotoxicity is complicated and remains unresolved. Results of an in vitro study assessing mitochrondrial membrane potential in neuroblastoma cells (38) are suggestive of a non-apoptotic pathway; however, up-regulation of caspase activity in neuroblastoma cells (39) 8 of mice exposed to AZA1 (40) . Nonetheless, such discrepancies may be explained, in part, by AZA1 causing simultaneous induction of both necrotic and apoptotic mechanisms (31) .
Due to difficulties in obtaining sufficient amounts of purified material, much less information is available regarding the toxicological properties of the other natural AZA analogs. At relatively high concentrations (i.e., 50-1000 nM), AZA2, AZA3, AZA4, and AZA5 have been shown to have various effects on intracellular pH, cytosolic calcium, and cAMP in lymphocytes (29, 41, 42 (31) . This study provided the first side-by-side evidence for potency differences among these regulated toxins.
Clearly, structure-activity relationship (SAR) studies are very important from a regulatory perspective, but to date, have been hindered by the lack of pure material. As such, many of the previous SAR studies have been confined to the study of AZA1 and its synthetic fragments (43, 44) ; however, purified AZA2 and AZA3 have recently become available commercially (45) .
This supply of new material enabled the present comparative study in which we characterized the toxicological effects of the currently regulated AZAs (i.e., AZA1, AZA2, AZA3) in an in vitro model system based on the Jurkat T lymphocyte cell line.
MATERIALS AND METHODS
Toxin Isolation. AZA1, AZA2 and AZA3 were isolated from whole cooked mussel tissue (M.
edulis) collected in 2005 from Bruckless, Donegal, Ireland. The toxins were purified using a 7 step isolation procedure, the details of which have recently been reported (46) . Toxin purity (>95%) was confirmed by LC-MS/MS and NMR spectroscopy and this material was used to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 using a Fluostar microplate reader (BMG Technologies, NC, USA). All data (mean ± SE) from 3 or more separate experiments were normalized to percentage relative to vehicle controls.
Morphological characteristics. T lymphocytes were diluted in fresh medium to 3-4 x 10 5 cells/mL and seeded in 24-well plates containing 500 µL per well (1.5-2 x 10 5 cells/well). Cells were exposed to AZA concentrations approximately twice the EC 50 concentration (Table 1 and In addition, each cytotoxicity experiment was performed using triplicate wells. Cytotoxicity data were blank corrected and normalized to the vehicle control (% viability). EC 50 and 95%
confidence interval determinations were calculated using three parameter, variable slope, nonlinear regression analysis (GraphPad Prism, ver. 5.0c, San Diego, USA).
RESULTS
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Chemical Research in Toxicology   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Effect of AZA Analogs on Cell Viability. Jurkat T lymphocyte cells were exposed to natural analogs of AZA (i.e., AZA1, AZA2, AZA3) to assess cellular viability and determine relative potencies. AZAs were tested across a range of concentrations and time points (24, 48 , and 72 h).
Each AZA analog induced time-and concentration-dependent cytotoxicity to the lymphocyte cells ( Figure 2 ) but differed in their relative potencies. Cytotoxicity was minimal at 24 h with cell viability ranging from 78%-86% for the three AZA analogs. Longer exposure times of 48
and 72 h for each AZA analog resulted in a step-wise reduction of viability causing more complete cytotoxicity (20-21% viability at 48 h and 7-12% viability at 72 h) at AZA1
concentrations > 1 nM, AZA2 concentrations > 0.1 nM, and AZA3 concentrations > 0.5 nM.
EC 50 values (including 95% confidence intervals) are presented for each AZA analog at each time point in Table 1 . The mean EC 50 value for each AZA analog across all three time points was 2.5 nM for AZA1, 0.30 nM for AZA2, and 0.55 nM for AZA3. As such, AZA2 and AZA3 were 8.3-fold and 4.5-fold more potent than AZA1, respectively (Table 1) .
Morphological Changes of Lymphocyte Cells Following Exposure to AZA Analogs.
Photomicrographs of control T lymphocyte cells illustrated that they were clearly intact with no signs of lysis and exhibited cytosolic extensions that have been identified as pseudopodia or "false feet" ( Figure 3A , B, and C; see arrows). However, lymphocyte cells exposed to the AZA analogs suggest a variety of cytolytic effects. Cells exposed to 5 nM AZA1 displayed a lack of cellular integrity (particularly at 48 and 72 h) as revealed by lysed cells and debris, organelle protrusion with concurrent flattening of cells, and a distinct lack of pseudopodia ( Figure 3D , E, and F). Although cell diameter was significantly (p < 0.05) increased at 72 h, this appears to be Page 11 of 34
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Cells treated with AZA2 and AZA3 also showed time-dependent cytolysis with some features (i.e., lack of cellular integrity, organelle protrusion, flattening of cells) in common with AZA1-treated cells ( Figure 3G , H, I, and Figure 3J , K, L, respectively). However, despite clear cytolysis, pseudopodia were still present in each of these treatment regimes (as indicated by arrows). Apparent increases in cell diameter were also statistically significant (p < 0.05) for AZA2 at 72 h and AZA3 at 48 and 72 h (data not shown), but similar to AZA1 these changes are attributed to cell flattening and not actual swelling. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14
Effects of AZA Analogs on
The cytotoxic potential of AZA1 towards various cell types is well established and has been unambiguously demonstrated using microscopy techniques (24, 27, 34, 39) , cellular protein content (27) , DNA content and synthesis (27, 48) , release of cytosolic enzymes (31, 36) , and mitochondrial activity (24, 31) . Within the current study, the cytotoxic potential of AZA1, as well as AZA2 and AZA3, was confirmed using human Jurkat T lymphocytes as the model cell line, selected based on previous work demonstrating its high level of sensitivity to AZA1 (28) .
Each analog induced cytotoxicity in a time-and concentration-dependent manner, exhibiting (21) (based on minimal lethal concentrations) that have been implemented by the EU for regulatory purposes (23). However, the TEFs estimated based on these in vivo studies (23) suggest less drastic potency differences between these three AZA analogs as compared to the in vitro data. In contrast, the relative cytotoxic potencies of these same AZA analogs differ when assessed in neocortical neurons (i.e., AZA3 > AZA2 ~ AZA1) and by cytotoxicity (via LDH release) and calcium ion oscillation suppression (31) (i.e., AZA3 > AZA2 > AZA1), further supporting cell type differences in sensitivity. As such, methylation at C8 (AZA2) confers the highest degree of cytotoxic potency in T lymphocytes, whereas de-methylation at C22 (AZA3) confers the highest degree of potency in neocortical neurons, suggesting that structural changes in analogs yield variable toxicities in different cell lines.
An interesting and rather unusual observation compared to other phycotoxin classes is that the various AZA analogs showing structural differences at the C3, C8, C22, and/or the C23 positions, elicit different cellular effects and in turn, may be affecting more than one molecular target. This was suspected early on by the Botana group when studying secondary messenger systems (28, 29, 38, 41) and also reported more recently by the Murray group when they observed a discrepancy between the effects of AZA1 and fragments of AZA1 on cytotoxicity and spontaneous calcium ion oscillations (31) . We have documented previously the total retraction of pseudopodia in T lymphocyte cells caused by AZA1 in a time-dependent manner that was specific to AZA1 but not elicited by a wide variety of other marine phycotoxins (24) . In the present study, AZA1 caused similar retraction of pseudopodia in a concentration-dependent manner with no observed effect on ruffle formation. On the contrary, exposure of T lymphocyte cells to AZA2 and AZA3 had no effect on morphological characteristics or number of pseudopodia. The mechanisms involved in pseudopodia assembly are not completely understood but they are known to involve nucleation of actin filaments by nucleation factors such as formin proteins (49) . Despite evidence that AZA1 does not directly alter actin polymerization and/or depolymerization (7), actin nucleation factors such as formin FRL2 have been shown to be directly involved in the formation and length of pseudopodia in Jurkat T lymphocyte cells (50) , and may be affected by AZA1. The functional relevance of pseudopodia inhibition by AZA1 has not yet been examined but may compromise immune function in organisms exposed to AZAs. (44) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 simultaneous appearance of cellular markers for both apoptosis and necrosis across a variety of cell lines (7, 31, 38, 39) and following in vivo exposure (17, 18).
CONCLUSIONS
Our data provide evidence that AZA1, AZA2, and AZA3 are highly cytotoxic to T lymphocytes and that there are significant differences in their relative potencies that correlate well with in vivo studies. Furthermore, specific cellular effects such as pseudopodial retraction
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